Aveo Oncology gets initial warning from Nasdaq that it could be delisted

A Cambridge biotech struggling to claw its way back after a devastating FDA rejection in 2013, Aveo Oncology has been notified that its stock stock price is too low to remain on the Nasdaq Global Market...